Leon Kircik

8PUBLICATIONS
62CO-AUTHORS
AllergyEpidemiological methodsPharmaceutical delivery technologiesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 22, 2026
Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic Dermatitis.

|Oct 02, 2026
Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison.

|May 21, 2026
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

|Jul 22, 2025
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.

Andrew F Alexis, Leon Kircik, Raj Chovatiya

|Mar 21, 2025
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials.

April W Armstrong, Leon Kircik, Linda Stein Gold

|Jul 12, 2024
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies.

Eric L Simpson, Leon Kircik, Andrew Blauvelt

Pageof 2

Frequent Collaborators

3 joint publications

April W Armstrong

2 joint publications

Andreas Wollenberg

2 joint publications

Andrew Blauvelt

2 joint publications

Linda Stein Gold